Qinlock™ (ripretinib) – New orphan drug approval
May 15, 2020 - The FDA announced the approval of Deciphera Pharmaceuticals’ Qinlock (ripretinib), for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib (eg, Gleevec®).
Top